Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Mixed Premarket Friday

09/17/2021 | 09:13am EST


ę MT Newswires 2021
All news about PROTAGONIST THERAPEUTICS, INC.
11/16Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
11/15Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
11/15JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
11/15Protagonist Therapeutics, Inc. Announces Positive Phase 2A Data Supporting the Potentia..
CI
11/11Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
PR
11/05Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Pol..
AQ
11/03PROTAGONIST THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/03PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/03Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corp..
PU
11/03Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -127 M - -
Net cash 2021 248 M - -
P/E ratio 2021 -11,4x
Yield 2021 -
Capitalization 1 476 M 1 476 M -
EV / Sales 2021 51,5x
EV / Sales 2022 48,5x
Nbr of Employees 116
Free-Float 98,8%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 30,93 $
Average target price 59,00 $
Spread / Average Target 90,8%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.53.42%1 476
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625